DAILYZ HEALTH NEWS

The FDA proposed reclassifying Mycobacterium tuberculosis immunity tests from Class III to Class II devices with new special controls.

Health

March 31, 2026 Evan Vega

Simple Therapies Outperform Drugs in Major Analysis of 10,000 Knee Arthritis Patients

A global analysis of 10,000 knee arthritis patients found knee braces, water therapy, and exercise outperform drug treatments in pain relief and function.

Health

March 30, 2026 Evan Vega

FDA Greenlights Avlayah (tividenofusp alfa-eknm) for Hunter Syndrome in Specific Patients on March 24

The FDA approved Avlayah (tividenofusp alfa-eknm) for treating neurologic Hunter syndrome in pediatric patients weighing at least 5 kg.

Health

March 30, 2026 Evan Vega

FDA Approves Lifyorli (relacorilant) for Platinum-Resistant Ovarian Cancer on March 25

The FDA approved relacorilant (Lifyorli) with nab-paclitaxel for platinum-resistant ovarian cancer, based on improved progression-free survival in a phase 3 trial.

Health

March 29, 2026 Evan Vega

Sotyktu (deucravacitinib) Awaits FDA Decision by March 6 for Adults with Active Psoriatic Arthritis

The FDA approved Sotyktu (deucravacitinib) on March 6, 2026, for adults with active psoriatic arthritis based on positive phase 3 trial results.

Health

March 29, 2026 Evan Vega

FDA Approves Nivolumab Addition to AVD Chemotherapy for Patients 12 and Older with Hodgkin Lymphoma

The FDA approved nivolumab with AVD chemotherapy for patients 12+ with untreated Stage III/IV classical Hodgkin lymphoma.

Health

March 28, 2026 Evan Vega

FDA Greenlights Nivolumab Plus AVD Regimen for Untreated Classic Hodgkin Lymphoma in March

The FDA approved nivolumab plus AVD for untreated Stage III/IV classical Hodgkin lymphoma in patients aged 12 and older.

Health

March 28, 2026 Evan Vega

GSK Resubmits Tebipenem HBr NDA for Complicated UTIs After Phase 3 Non-Inferiority Data

GlaxoSmithKline resubmitted its NDA for tebipenem HBr to the FDA for complicated UTIs after positive Phase 3 non-inferiority trial results.

Health

March 26, 2026 Evan Vega

Gilead Submits NDA for Bulevirtide, First Potential HDV Treatment, Backed by Phase 3 MYR301 Data

Gilead Sciences submitted an NDA to the FDA for bulevirtide 10 mg to treat chronic hepatitis delta virus, supported by Phase 3 MYR301 data.

Health

March 26, 2026 Evan Vega

FDA Extends Review of Reproxalap for Dry Eye Disease to March 16 Amid Clinical Study Requests

The FDA extended its review of Aldeyra’s reproxalap for dry eye disease to March 16, 2026, after requesting a clinical study report.

DAILYZ HEALTH NEWS

DAILYZ HEALTH NEWS

AMA urges Congress to impose safety rules on AI mental-health chatbots as clinical risks draw scrutiny

Health-system and regulatory watchers brace for new FDA and HHS actions as mifepristone, vaccines, and psychedelic medicine dominate policy debate

Tenerife grapples with hantavirus response as WHO issues follow-up guidance amid local public health monitoring

Retrospective study links GLP-1 drugs to lower breast cancer mortality and recurrence, but experts question data quality

Global health officials race to contain multi-country hantavirus spread after deadly cruise-linked outbreak kills three, including Dutch couple

AMA urges Congress to impose safety rules on AI mental-health chatbots as clinical risks draw scrutiny

Health-system and regulatory watchers brace for new FDA and HHS actions as mifepristone, vaccines, and psychedelic medicine dominate policy debate

Tenerife grapples with hantavirus response as WHO issues follow-up guidance amid local public health monitoring

Retrospective study links GLP-1 drugs to lower breast cancer mortality and recurrence, but experts question data quality

AMA urges Congress to impose safety rules on AI mental-health chatbots as clinical risks draw scrutiny

Health-system and regulatory watchers brace for new FDA and HHS actions as mifepristone, vaccines, and psychedelic medicine dominate policy debate

Tenerife grapples with hantavirus response as WHO issues follow-up guidance amid local public health monitoring

Retrospective study links GLP-1 drugs to lower breast cancer mortality and recurrence, but experts question data quality

Global health officials race to contain multi-country hantavirus spread after deadly cruise-linked outbreak kills three, including Dutch couple

AMA urges Congress to impose safety rules on AI mental-health chatbots as clinical risks draw scrutiny

Health-system and regulatory watchers brace for new FDA and HHS actions as mifepristone, vaccines, and psychedelic medicine dominate policy debate

Tenerife grapples with hantavirus response as WHO issues follow-up guidance amid local public health monitoring

Retrospective study links GLP-1 drugs to lower breast cancer mortality and recurrence, but experts question data quality

AMA urges Congress to impose safety rules on AI mental-health chatbots as clinical risks draw scrutiny

Health-system and regulatory watchers brace for new FDA and HHS actions as mifepristone, vaccines, and psychedelic medicine dominate policy debate

Tenerife grapples with hantavirus response as WHO issues follow-up guidance amid local public health monitoring

Retrospective study links GLP-1 drugs to lower breast cancer mortality and recurrence, but experts question data quality

Global health officials race to contain multi-country hantavirus spread after deadly cruise-linked outbreak kills three, including Dutch couple

FDA Proposes Reclassifying Mycobacterium Tuberculosis Immunity Tests to Class II Devices

Simple Therapies Outperform Drugs in Major Analysis of 10,000 Knee Arthritis Patients

FDA Greenlights Avlayah (tividenofusp alfa-eknm) for Hunter Syndrome in Specific Patients on March 24

FDA Approves Lifyorli (relacorilant) for Platinum-Resistant Ovarian Cancer on March 25

Sotyktu (deucravacitinib) Awaits FDA Decision by March 6 for Adults with Active Psoriatic Arthritis

FDA Approves Nivolumab Addition to AVD Chemotherapy for Patients 12 and Older with Hodgkin Lymphoma

FDA Greenlights Nivolumab Plus AVD Regimen for Untreated Classic Hodgkin Lymphoma in March

GSK Resubmits Tebipenem HBr NDA for Complicated UTIs After Phase 3 Non-Inferiority Data

Gilead Submits NDA for Bulevirtide, First Potential HDV Treatment, Backed by Phase 3 MYR301 Data

FDA Extends Review of Reproxalap for Dry Eye Disease to March 16 Amid Clinical Study Requests